

Craig C Hofmeister

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9487069/publications.pdf>

Version: 2024-02-01

241
papers

8,883
citations

71102

41
h-index

46799

89
g-index

244
all docs

244
docs citations

244
times ranked

11386
citing authors

#	ARTICLE	IF	CITATIONS
1	Benefits of Autologous Stem Cell Transplantation for Elderly Myeloma Patients in the Last Quarter of Life. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 75.e1-75.e7.	1.2	5
2	A phase 1 clinical trial of oral eltanexor in patients with relapsed or refractory multiple myeloma. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	11
3	Impact of concurrent gabapentin or pregabalin with high-dose melphalan in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. <i>Pharmacotherapy</i> , 2022, 42, 233-240.	2.6	1
4	Determinants of Neutralizing Antibody Response After SARS CoV-2 Vaccination in Patients With Myeloma. <i>Journal of Clinical Oncology</i> , 2022, 40, 3057-3064.	1.6	31
5	A Single Nucleotide Polymorphism (SNP) in the <i>SLC22A3</i> Transporter Gene Is Associated With the Severity of Oral Mucositis in Multiple Myeloma Patients Receiving Autologous Stem Cell Transplant Followed by Melphalan Therapy. <i>Anticancer Research</i> , 2022, 42, 385-395.	1.1	4
6	Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting. <i>Leukemia</i> , 2021, 35, 189-200.	7.2	56
7	Natural history of multiple myeloma patients refractory to venetoclax: A single center experience. <i>American Journal of Hematology</i> , 2021, 96, E68-E71.	4.1	7
8	A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 87, 599-611.	2.3	16
9	Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 3178-3189.	7.0	15
10	Venetoclax sensitivity in multiple myeloma is associated with B-cell gene expression. <i>Blood</i> , 2021, 137, 3604-3615.	1.4	44
11	Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 519-531.	4.4	8
12	Early phase clinical studies of AR-42, a histone deacetylase inhibitor, for neurofibromatosis type 2-associated vestibular schwannomas and meningiomas. <i>Laryngoscope Investigative Otolaryngology</i> , 2021, 6, 1008-1019.	1.5	14
13	Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia. <i>Blood Cancer Discovery</i> , 2021, 2, 600-615.	5.0	15
14	Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2021, 46, 807-816.	1.6	1
15	Daratumumab with Pomalidomide and Dexamethasone at First Relapse in Relapsed and/or Refractory Multiple Myeloma (RRMM) Patients. <i>Blood</i> , 2021, 138, 1616-1616.	1.4	0
16	BRAF Mutations and Inflammatory Gene Expression in Myeloma Cells from Patients with Renal Dysfunction. <i>Blood</i> , 2021, 138, 1624-1624.	1.4	0
17	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) <i>TJ ETQq1 1 0.784314 rgBT /Over</i>		
18	Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies. <i>Blood</i> , 2021, 138, 3134-3134.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long-Term Follow-Up. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 44-49.	2.0	4
20	Downregulation of PA28 β induces proteasome remodeling and results in resistance to proteasome inhibitors in multiple myeloma. <i>Blood Cancer Journal</i> , 2020, 10, 125.	6.2	7
21	Characterizing Pain Experiences: African American Patients With Multiple Myeloma Taking Around-the-Clock Opioids. <i>Clinical Journal of Oncology Nursing</i> , 2020, 24, 538-546.	0.6	5
22	Association of ANRIL Polymorphism With Overall Survival in Adult Patients With Hematologic Malignancies After Allogeneic Hematopoietic Stem Cell Transplantation. <i>Anticancer Research</i> , 2020, 40, 5707-5713.	1.1	4
23	Development of a method for clinical pharmacokinetic testing to allow for targeted Melphalan dosing in multiple myeloma patients undergoing autologous transplant. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 2165-2173.	2.4	5
24	Daratumumab monotherapy for patients with intermediate-risk or high-risk smoldering multiple myeloma: a randomized, open-label, multicenter, phase 2 study (CENTAURUS). <i>Leukemia</i> , 2020, 34, 1840-1852.	7.2	55
25	Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. <i>Leukemia</i> , 2020, 34, 2430-2440.	7.2	54
26	Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1928-1937.	1.6	148
27	Chromatin Accessibility Identifies Regulatory Elements Predictive of Oncogene Expression in Multiple Myeloma. <i>Blood</i> , 2020, 136, 31-32.	1.4	0
28	Role of clonoSEQ [®] , a Next-Generation Sequencing (NGS) Assay and PET/CT As a Measure of Minimal Residual Disease Negativity Among Patients with Multiple Myeloma. <i>Blood</i> , 2020, 136, 50-51.	1.4	0
29	Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. <i>Journal of Geriatric Oncology</i> , 2019, 10, 479-485.	1.0	64
30	Clinical and cost outcomes of pre-emptive plerixafor administration in patients with multiple myeloma undergoing stem cell mobilization. <i>Leukemia Research</i> , 2019, 85, 106215.	0.8	8
31	XRCC1-mediated DNA repair is associated with progression-free survival of multiple myeloma patients after autologous stem cell transplant. <i>Molecular Carcinogenesis</i> , 2019, 58, 2327-2339.	2.7	7
32	Population pharmacokinetics of lenalidomide in patients with B-cell malignancies. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 924-934.	2.4	8
33	Registering a CD38 antibody upfront for multiple myeloma. <i>Lancet, The</i> , 2019, 394, 3-4.	13.7	0
34	Multiple myeloma immunoglobulin lambda translocations portend poor prognosis. <i>Nature Communications</i> , 2019, 10, 1911.	12.8	109
35	Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies. <i>European Journal of Haematology</i> , 2019, 102, 494-503.	2.2	11
36	Daratumumab in multiple myeloma. <i>Cancer</i> , 2019, 125, 2364-2382.	4.1	100

#	ARTICLE	IF	CITATIONS
37	BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkinâ€™s lymphomas. Bone Marrow Transplantation, 2019, 54, 1553-1561.	2.4	6
38	Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone. Blood Cancer Journal, 2019, 9, 94.	6.2	104
39	Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease?. Bone Marrow Transplantation, 2019, 54, 913-916.	2.4	2
40	A Single Nucleotide Polymorphism in <i>SLC7A5</i> Was Associated With Clinical Response in Multiple Myeloma Patients. Anticancer Research, 2019, 39, 67-72.	1.1	10
41	Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents. Cancer, 2019, 125, 416-423.	4.1	36
42	Most multiple myeloma patients have low testosterone. Leukemia and Lymphoma, 2019, 60, 836-838.	1.3	3
43	BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 1107-1115.	2.0	9
44	Early alterations in stem-like/marrow-resident T cells and innate and myeloid cells in preneoplastic gammopathy. JCI Insight, 2019, 4, .	5.0	107
45	MiR-16 regulates crosstalk in NF-Î³B tolerogenic inflammatory signaling between myeloma cells and bone marrow macrophages. JCI Insight, 2019, 4, .	5.0	33
46	Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma. Blood, 2019, 134, 1816-1816.	1.4	1
47	Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials. Blood, 2019, 134, 4525-4525.	1.4	1
48	Ixazomib or Lenalidomide Maintenance Following Autologous Stem Cell Transplantation and Ixazomib, Lenalidomide, and Dexamethasone (IRD) Consolidation in Patients with Newly Diagnosed Multiple Myeloma: Results from a Large Multi-Center Randomized Phase II Trial. Blood, 2019, 134, 602-602.	1.4	10
49	The Role of Proteasome Activator PA28Î± in Multiple Myeloma. Blood, 2019, 134, 5499-5499.	1.4	0
50	Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrangement Driven Trial,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5		
51	Improved Treatment Related Mortality in Patients with Primary Systemic Amyloidosis (AL Amyloidosis) undergoing Autologous Hematopoietic Stem Cell Transplant (aHSCT).., 2019, 2, 12-18.		0
52	Ninety-minute daratumumab infusion is safe in multiple myeloma. Leukemia, 2018, 32, 2495-2518.	7.2	53
53	Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients. Bone Marrow Transplantation, 2018, 53, 1418-1427.	2.4	19
54	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 11-20.	4.9	142

#	ARTICLE	IF	CITATIONS
55	Importin- β 2 and exportin-5 are strong biomarkers of productive reoviral infection of cancer cells. <i>Annals of Diagnostic Pathology</i> , 2018, 32, 28-34.	1.3	2
56	Pharmacokineticâ€¦Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving Highâ€¦Dose Melphalan for Autologous Stem Cell Transplant. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 748-758.	2.5	11
57	Twiceâ€¦weekly ixazomib in combination with lenalidomideâ€¦dexamethasone in patients with newly diagnosed multiple myeloma. <i>British Journal of Haematology</i> , 2018, 182, 231-244.	2.5	30
58	Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. <i>Oncolmmunology</i> , 2018, 7, e1486948.	4.6	41
59	Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia. <i>Blood</i> , 2018, 131, 855-863.	1.4	105
60	Ixazomib-Lenalidomide-Dexamethasone (IRd) Consolidation Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Large Multi-Center Phase II Trial. <i>Blood</i> , 2018, 132, 123-123.	1.4	6
61	Outcomes and Clinical Features of Patients with 1q+ Multiple Myeloma Treated with Lenalidomide, Bortezomib, and Dexamethasone. <i>Blood</i> , 2018, 132, 3241-3241.	1.4	1
62	Updated Results from the Phase 2 Centaurus Study of Daratumumab (DARA) Monotherapy in Patients with Intermediate-Risk or High-Risk Smoldering Multiple Myeloma (SMM). <i>Blood</i> , 2018, 132, 1994-1994.	1.4	10
63	Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses. <i>Blood</i> , 2018, 132, 2655-2655.	1.4	2
64	Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy. <i>Blood</i> , 2018, 132, 1884-1884.	1.4	1
65	Outcomes of Myeloma Patients with t(11;14) Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. <i>Blood</i> , 2018, 132, 3282-3282.	1.4	11
66	Safety and Efficacy of Evomelaâ„¢ in Myeloma Autotransplants. <i>Blood</i> , 2018, 132, 3446-3446.	1.4	2
67	Efficacy of Induction Therapy with Lenalidomide, Bortezomib, and Dexamethasone (RVD) in 1000 Newly Diagnosed Multiple Myeloma (MM) Patients. <i>Blood</i> , 2018, 132, 3294-3294.	1.4	2
68	Differences in Presentation and Survival Outcomes for African American Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2018, 132, 5647-5647.	1.4	3
69	Impact of Early Progression on Long Term Outcomes Among Myeloma Patients Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Induction Therapy. <i>Blood</i> , 2018, 132, 3302-3302.	1.4	0
70	The Impact of a Physical Activity Intervention Can be Accurately Assessed By Smart Watches in Patients Completing Autologous Stem Cell Transplantation for Lymphoma or Multiple Myeloma: Results of a Feasibility Study. <i>Blood</i> , 2018, 132, 5911-5911.	1.4	1
71	Polymorphism in <i>ANRIL</i> is associated with relapse in patients with multiple myeloma after autologous stem cell transplant. <i>Molecular Carcinogenesis</i> , 2017, 56, 1722-1732.	2.7	28
72	A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas. <i>Leukemia and Lymphoma</i> , 2017, 58, 2310-2318.	1.3	43

#	ARTICLE	IF	CITATIONS
73	G-CSF improves safety when you start the day after autologous transplant in multiple myeloma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2947-2951.	1.3	4
74	Multiple Myeloma, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 230-269.	4.9	166
75	Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study. <i>Lancet Haematology</i> , 2017, 4, e24-e34.	4.6	33
76	Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. <i>Lancet Haematology</i> , 2017, 4, e431-e442.	4.6	132
77	Reolysin and Histone Deacetylase Inhibition in the Treatment of Head and Neck Squamous Cell Carcinoma. <i>Molecular Therapy - Oncolytics</i> , 2017, 5, 87-96.	4.4	33
78	Efficacy and Safety of Long-Term Ixazomib Maintenance Therapy in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Not Undergoing Transplant: An Integrated Analysis of Four Phase 1/2 Studies. <i>Blood</i> , 2017, 130, 902-902.	1.4	4
79	How to Integrate Elotuzumab and Daratumumab Into Therapy for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2016, 34, 4421-4430.	1.6	20
80	NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 389-400.	4.9	62
81	Antithymocyte Globulin (ATG) 4.5 Vs. 6.0 Mg/Kg in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S316-S317.	2.0	0
82	Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. <i>Bone Marrow Transplantation</i> , 2016, 51, 1241-1244.	2.4	53
83	Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1. <i>Blood</i> , 2016, 127, 2693-2700.	1.4	66
84	A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma. <i>British Journal of Haematology</i> , 2016, 174, 323-325.	2.5	22
85	Proteomic characterization of circulating extracellular vesicles identifies novel serum myeloma associated markers. <i>Journal of Proteomics</i> , 2016, 136, 89-98.	2.4	68
86	Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 658-668.	2.0	23
87	Histone Deacetylase Inhibitors Enhance the Therapeutic Potential of Reovirus in Multiple Myeloma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 830-841.	4.1	35
88	Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 71-79.	2.0	11
89	Tocilizumab for steroid refractory acute graft-versus-host disease. <i>Leukemia and Lymphoma</i> , 2016, 57, 81-85.	1.3	35
90	Anti-Depressant Use in Patients with Multiple Myeloma Less Common Than Expected. <i>Blood</i> , 2016, 128, 2420-2420.	1.4	3

#	ARTICLE	IF	CITATIONS
91	Exploring the Possibility of Using Herpes Simplex Virus in Oncolytic Virotherapy of Multiple Myeloma. <i>Blood</i> , 2016, 128, 4467-4467.	1.4	4
92	Daratumumab Impairs Myeloma Cell Adhesion Mediated Drug Resistance through CD38 Internalization. <i>Blood</i> , 2016, 128, 4479-4479.	1.4	3
93	A Phase 1/2 Study of the Second Generation Selective Inhibitor of Nuclear Export (SINE) Compound, KPT-8602, in Patients with Relapsed Refractory Multiple Myeloma. <i>Blood</i> , 2016, 128, 4509-4509.	1.4	10
94	G-CSF Starting Day +1 after Autologous Transplant Is Safer Than Day +5 or Day +7 in Patients with Multiple Myeloma. <i>Blood</i> , 2016, 128, 5790-5790.	1.4	4
95	Relative Clone Size By FISH of Both Del(13q) and Del(17p) Independently Impact Overall Survival. <i>Blood</i> , 2016, 128, 4444-4444.	1.4	0
96	Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-Versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 3409-3409.	1.4	0
97	Psychosocial Risk Is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016, 128, 1241-1241.	1.4	0
98	Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2016, 128, 3410-3410.	1.4	0
99	Evaluation of Immune Recovery Following Autologous Hematopoietic Cell Transplantation in HIV-Related Lymphoma: Results of the BMT CTN 0803/AMC 071 Trial. <i>Blood</i> , 2016, 128, 1346-1346.	1.4	12
100	A Potential Role for Auto-Graft Immune Cell Subsets to Influence Post-Transplant Outcomes in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S131.	2.0	0
101	Lenalidomide and vorinostat maintenance after autologous transplant in multiple myeloma. <i>British Journal of Haematology</i> , 2015, 171, 74-83.	2.5	20
102	A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. <i>Clinical Cancer Research</i> , 2015, 21, 4055-4061.	7.0	154
103	A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 1043-1049.	1.3	7
104	Autologous hematopoietic stem cell transplant induces the molecular aging of T-cells in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2015, 50, 1379-1381.	2.4	36
105	Phase 1/2 dose-escalation study of marizomib (MRZ, NPI-0052) plus low dose dexamethasone (DEX) in patients with relapsed and refractory multiple myeloma; study NPI-0052-101 (NCT00461045). <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e271-e272.	0.4	0
106	Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. <i>Leukemia and Lymphoma</i> , 2015, 56, 1058-1065.	1.3	19
107	Reolysin Combined with Carfilzomib for Treatment of Relapsed Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 1835-1835.	1.4	4
108	First Interim Results of a Phase I/II Study of Lenalidomide in Combination with Anti-PD-1 Monoclonal Antibody MDV9300 (CT-011) in Patients with Relapsed/Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 1838-1838.	1.4	11

#	ARTICLE	IF	CITATIONS
109	A Phase 1, Multicenter Study of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Patients with Proteasome Inhibitor Exposed and Lenalidomide-Refractory Myeloma (Trial MM-005). <i>Blood</i> , 2015, 126, 3036-3036.	1.4	12
110	TG02, an Oral CDK9-Inhibitor, in Combination with Carfilzomib Demonstrated Objective Responses in Carfilzomib Refractory Multiple Myeloma Patients. <i>Blood</i> , 2015, 126, 3052-3052.	1.4	8
111	Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients. <i>Blood</i> , 2015, 126, 3200-3200.	1.4	2
112	The Majority of Myeloma Patients Are Vitamin D Deficient, Unrelated to Survival or Cytogenetics. <i>Blood</i> , 2015, 126, 5336-5336.	1.4	7
113	Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM). <i>Blood</i> , 2015, 126, 728-728.	1.4	9
114	Updated analysis of CALGB/ECOG/BMT CTN 100104: Lenalidomide (Len) vs. placebo (PBO) maintenance therapy after single autologous stem cell transplant (ASCT) for multiple myeloma (MM).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8523-8523.	1.6	15
115	HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide. <i>Oncotarget</i> , 2015, 6, 31134-31150.	1.8	38
116	Multiple Myeloma, Version 2.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1398-1435.	4.9	55
117	Proteomic Characterization of Circulating Extracellular Vesicles Identifies Novel Serum Myeloma Associated Markers. <i>Blood</i> , 2015, 126, 1814-1814.	1.4	0
118	The Majority of Myeloma Patients Are Hypogonadal but This Is Not Associated with High Risk Cytogenetics. <i>Blood</i> , 2015, 126, 5329-5329.	1.4	0
119	Small RNA Deep Sequencing Highlights the Important Contribution of Mirnas in Regulating IRF4/c-Myc Axis in Myeloma Development. <i>Blood</i> , 2015, 126, 1791-1791.	1.4	0
120	Comparison of Two Doses of Antithymocyte Globulin (ATG) in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). <i>Blood</i> , 2015, 126, 4328-4328.	1.4	0
121	The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma. <i>Bone Marrow Transplantation</i> , 2014, 49, 1323-1329.	2.4	21
122	Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma. <i>British Journal of Cancer</i> , 2014, 111, 272-280.	6.4	42
123	The potential of miRNAs as biomarkers for multiple myeloma. <i>Expert Review of Molecular Diagnostics</i> , 2014, 14, 947-959.	3.1	23
124	Novel gelsolin variant as the cause of nephrotic syndrome and renal amyloidosis in a large kindred. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2014, 21, 110-112.	3.0	35
125	Genetic Modification of T Cells Redirected toward CS1 Enhances Eradication of Myeloma Cells. <i>Clinical Cancer Research</i> , 2014, 20, 3989-4000.	7.0	103
126	A Phase I Trial of Single-Agent Reolysin in Patients with Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2014, 20, 5946-5955.	7.0	72

#	ARTICLE	IF	CITATIONS
127	A phase I trial of flavopiridol in relapsed multiple myeloma. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 249-257.	2.3	30
128	Sensitive liquid chromatography/mass spectrometry methods for quantification of pomalidomide in mouse plasma and brain tissue. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 262-268.	2.8	21
129	Circulating miRNA markers show promise as new prognosticators for multiple myeloma. <i>Leukemia</i> , 2014, 28, 1922-1926.	7.2	55
130	Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. <i>Supportive Care in Cancer</i> , 2014, 22, 2911-2916.	2.2	14
131	High-Risk Myeloma: When To Transplant Or Not. <i>Seminars in Oncology</i> , 2014, 41, e1-e9.	2.2	0
132	Utility of CMV PCR in the Evaluation of Allograft Recipients Presenting with Diarrhea. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, S250-S251.	2.0	0
133	FLT3L and Plerixafor Combination Increases Hematopoietic Stem Cell Mobilization and Leads to Improved Transplantation Outcome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 309-313.	2.0	17
134	Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. <i>Blood</i> , 2014, 123, 1826-1832.	1.4	327
135	T-Cell p16INK4A Expression Increases Post-Transplant in Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 2023-2023.	1.4	2
136	2-Hour Cryotherapy Effectively Reduces Severe Mucositis Associated with High-Dose Melphalan Followed By Stem Cell Rescue: Results from a Randomized Trial. <i>Blood</i> , 2014, 124, 3960-3960.	1.4	3
137	Selinexor Demonstrates Marked Synergy with Dexamethasone (Sel-Dex) in Preclinical Models and in Patients with Heavily Pretreated Refractory Multiple Myeloma (MM). <i>Blood</i> , 2014, 124, 4773-4773.	1.4	8
138	Long Term Therapy with Lenalidomide in a patient with POEMS Syndrome. <i>European Journal of Case Reports in Internal Medicine</i> , 2014, 1, .	0.4	5
139	Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2014, 124, 2494-2494.	1.4	0
140	Development of a Predictive Pharmacokinetic and Pharmacodynamic Model to Personalize Melphalan Dosing in Autologous Transplant for Patients with Multiple Myeloma. <i>Blood</i> , 2014, 124, 1086-1086.	1.4	1
141	Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft Vs. Host Disease (aGVHD) in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo HSCT). <i>Blood</i> , 2014, 124, 3929-3929.	1.4	0
142	Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). <i>Blood</i> , 2014, 124, 1166-1166.	1.4	2
143	HDAC Inhibitor AR-42 Decreases CD44 Expression and Sensitizes Myeloma Cells to Lenalidomide. <i>Blood</i> , 2014, 124, 3377-3377.	1.4	1
144	Standard Pentostatin Dose Reductions in Renal Insufficiency Are Not Adequate: Selected Patients with Steroid-Refractory Acute Graft-Versus-Host Disease. <i>Clinical Pharmacokinetics</i> , 2013, 52, 705-712.	3.5	4

#	ARTICLE	IF	CITATIONS
145	Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1841-1849.	4.2	258
146	Characterization of Multiple Myeloma Vesicles by Label-Free Relative Quantitation. <i>Proteomics</i> , 2013, 13, n/a-n/a.	2.2	32
147	Impact of Atorvastatin On Cellular Immune of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S202.	2.0	0
148	Autologous Hematopoietic Stem Cell Transplant (aHSCT) is a Safe and Reasonable Treatment in Patients with Primary Systemic Amyloidosis (AL amyloidosis). <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S186.	2.0	0
149	Improved Survival of Patients (Pts) with Acute Graft-Versus-Host Disease (aGVHD) During Recent Years: Impact of Donor and Recipient Characteristics. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S320-S321.	2.0	0
150	Lower Dose of Antithymocyte Globulin (ATG) Decreases Infection Rate without Increasing Graft-Vs-Host Disease (GVHD) and Relapse in Patients Undergoing Reduced-Intensity (RIC) Allogeneic Hematopoietic Stem Cell Transplant (HSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, S304-S305.	2.0	0
151	Phase I pilot study of oxaliplatin, infusional 5-FU, and cetuximab in recurrent or metastatic head and neck cancer. <i>Medical Oncology</i> , 2013, 30, 358.	2.5	8
152	Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. <i>Leukemia and Lymphoma</i> , 2013, 54, 1658-1664.	1.3	63
153	MicroRNAs activate natural killer cells through Toll-like receptor signaling. <i>Blood</i> , 2013, 121, 4663-4671.	1.4	82
154	In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. <i>Journal of Experimental Medicine</i> , 2013, 210, 951-968.	8.5	121
155	Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma. <i>Blood</i> , 2013, 122, 1853-1853.	1.4	8
156	MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM). <i>Blood</i> , 2013, 122, 1969-1969.	1.4	12
157	A Phase I Trial Of Anti-KIR Monoclonal Antibody IPH2101 and Lenalidomide For Multiple Myeloma. <i>Blood</i> , 2013, 122, 3181-3181.	1.4	3
158	A Phase 1 Trial Of Reolysin Alone In Patients With Refractory Or Relapsed Multiple Myeloma. <i>Blood</i> , 2013, 122, 3208-3208.	1.4	1
159	Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): Final Phase 1 Results and Phase 2 Data. <i>Blood</i> , 2013, 122, 535-535.	1.4	18
160	MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose dexamethasone (PVD) in relapsed and/or refractory multiple myeloma (RRMM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 8584-8584.	1.6	3
161	FLT3L and AMD3100 Combination Increases Hematopoietic Stem Cell Mobilization and Leads To Improved Transplantation Outcome. <i>Blood</i> , 2013, 122, 901-901.	1.4	0
162	Efficacy and Safety Of Pomalidomide Plus Low-Dose Dexamethasone In Advanced Multiple Myeloma: Results Of Randomized Phase 2 and 3 Trials (MM-002/MM-003). <i>Blood</i> , 2013, 122, 3185-3185.	1.4	0

#	ARTICLE	IF	CITATIONS
163	Understanding The Differential Response Of Multiple Myeloma To Reovirus Treatment. <i>Blood</i> , 2013, 122, 3232-3232.	1.4	0
164	Reply to N. Chen et al. <i>Journal of Clinical Oncology</i> , 2012, 30, 341-342.	1.6	1
165	Unique Pattern of Renal κ Light Chain Amyloid Deposition With Histiocytic Transdifferentiation of Tubular Epithelial Cells. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1253-1257.	3.7	9
166	A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. <i>Blood</i> , 2012, 120, 4324-4333.	1.4	217
167	Improving Vaccination of Patients Pre and Post Bone Marrow Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, S380.	2.0	1
168	Chemotherapeutic Agents Increase the Risk for Pulmonary Function Test Abnormalities in Patients With Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2012, 12, 325-329.	0.4	8
169	Serum free light chains in myeloma patients with an intact M protein by immunofixation: potential roles for response assessment and prognosis during induction therapy with novel agents. <i>Hematological Oncology</i> , 2012, 30, 156-162.	1.7	10
170	Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2012, 366, 1770-1781.	27.0	1,024
171	Phase I Study of Aurora Kinase Inhibitor MLN8237 and Bortezomib in Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 1859-1859.	1.4	1
172	Post Autologous Transplant Vorinostat (SAHA) in High Risk Lymphoma: Phase 1 Study of Vorinostat Maintenance. <i>Blood</i> , 2012, 120, 2004-2004.	1.4	2
173	Phase I Study of AR-42 in Relapsed Multiple Myeloma and Lymphoma.. <i>Blood</i> , 2012, 120, 2955-2955.	1.4	4
174	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure. <i>Blood</i> , 2012, 120, 4070-4070.	1.4	1
175	Differential Distribution of Activated Innate and Adaptive Immune Subsets in G-CSF Mobilized Hematopoietic Stem Cell Allografts May Influence Incidence of Acute (aGVHD) and Chronic Graft-Versus-Host Disease (cGVHD). <i>Blood</i> , 2012, 120, 4192-4192.	1.4	1
176	The Hematopoietic Stem Cell Transplant Comorbidity Index (HCT-CI) Can Predict for Readmission Following Autologous Stem Cell Transplant for Lymphoma and Multiple Myeloma. <i>Blood</i> , 2012, 120, 4286-4286.	1.4	1
177	Pomalidomide (POM) with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Therapy with Lenalidomide (LEN) and Bortezomib (BORT): Updated Phase 2 Results and Age Subgroup Analysis. <i>Blood</i> , 2012, 120, 450-450.	1.4	11
178	Low Testosterone Levels Are Associated with Shorter Progression Free Survival in Multiple Myeloma. <i>Blood</i> , 2012, 120, 4978-4978.	1.4	1
179	MM-005: A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2012, 120, 727-727.	1.4	9
180	Immune Reconstitution and Quality of Life Analyses After Autologous Transplant for Multiple Myeloma. <i>Blood</i> , 2012, 120, 4460-4460.	1.4	0

#	ARTICLE	IF	CITATIONS
181	miRNA in Serum and Bone Marrow Plasma Cells From Multiple Myeloma Patients.. Blood, 2012, 120, 2921-2921.	1.4	0
182	Immune Reconstitution At Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease. Blood, 2012, 120, 1949-1949.	1.4	0
183	Phase I Trial of Lenalidomide + Vorinostat After Autologous Transplant in Multiple Myeloma.. Blood, 2012, 120, 3114-3114.	1.4	0
184	Immunomodulation of Both Donors and Recipients with Atorvastatin As a Strategy for the Prevention of Acute Graft-Versus-Host Disease (aGVHD): Results of Two Parallel Prospective Trials in Recipients of Matched Sibling Allogeneic Hematopoietic Cell Transplantation (alloHCT). Blood, 2012, 120, 1942-1942.	1.4	6
185	A Phase I Trial of the Anti-Inhibitory KIR Antibody, IPH2101, and Lenalidomide in Multiple Myeloma: Interim Results. Blood, 2012, 120, 4058-4058.	1.4	5
186	Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial. Blood, 2011, 118, 535-543.	1.4	82
187	IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood, 2011, 118, 6387-6391.	1.4	184
188	Initial genome sequencing and analysis of multiple myeloma. Nature, 2011, 471, 467-472.	27.8	1,288
189	Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. Hematological Oncology, 2011, 29, 202-210.	1.7	14
190	Phase I Trial of Lenalidomide and CCI-779 in Patients With Relapsed Multiple Myeloma: Evidence for Lenalidomide-CCI-779 Interaction via P-Glycoprotein. Journal of Clinical Oncology, 2011, 29, 3427-3434.	1.6	77
191	Phase 1 Clinical Evaluation of Twice-Weekly Marizomib (NPI-0052), a Novel Proteasome Inhibitor, in Patients with Relapsed/Refractory Multiple Myeloma (MM). Blood, 2011, 118, 302-302.	1.4	28
192	A Phase II Trial of Ofatumumab in Subjects with Waldenstrom's Macroglobulinemia,. Blood, 2011, 118, 3701-3701.	1.4	13
193	Randomized, Open Label Phase 1/2 Study of Pomalidomide (POM) Alone or in Combination with Low-Dose Dexamethasone (LoDex) in Patients (Pts) with Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide (LEN) and Bortezomib (BORT): Phase 2 Results. Blood, 2011, 118, 634-634.	1.4	9
194	The Multiple Myeloma Research Consortium (MMRC): Accelerated Start up and Accrual Metrics Speeds Drug Development. Blood, 2011, 118, 1024-1024.	1.4	0
195	TTP disease course is independent of myeloma treatment and response. American Journal of Hematology, 2010, 85, 304-306.	4.1	17
196	The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood, 2010, 116, 2286-2294.	1.4	716
197	Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. Leukemia and Lymphoma, 2010, 51, 243-251.	1.3	15
198	Conflicts of Interest, Authorship, and Disclosures in Industry-Related Scientific Publications-2. Mayo Clinic Proceedings, 2010, 85, 197-199.	3.0	5

#	ARTICLE	IF	CITATIONS
199	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone In Newly Diagnosed Multiple Myeloma (MM): Final Results of Phase I/II MMRC Trial. <i>Blood</i> , 2010, 116, 1937-1937.	1.4	1
200	Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104. <i>Blood</i> , 2010, 116, 37-37.	1.4	31
201	The Multiple Myeloma Research Consortium (MMRC) Model: Reduced Time to Trial Activation and Improved Accrual Metrics.. <i>Blood</i> , 2010, 116, 3803-3803.	1.4	2
202	Early Evidence of Anti-Lymphoma Activity of the Cyclin Dependent Kinase Inhibitor Dinaciclib (SCH) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50. <i>Blood</i> , 2010, 116, 3966-3966.	1.4	6
203	The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo. <i>PLoS ONE</i> , 2010, 5, e10941.	2.5	49
204	Analysis of 179 Patients with Newly Diagnosed Multiple Myeloma (MM) Treated with Novel Agents Followed by Autologous Stem Cell Transplantation (ASCT): a Retrospective Study. <i>Blood</i> , 2010, 116, 1343-1343.	1.4	0
205	IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody for Multiple Myeloma: Interm Phase 1 Trial Results and Correlative Biologic and Safety Data. <i>Blood</i> , 2010, 116, 1966-1966.	1.4	1
206	Early Versus Delayed Autologous Stem Cell Transplant In Patients Receiving Novel Therapies for Multiple Myeloma. <i>Blood</i> , 2010, 116, 3564-3564.	1.4	9
207	Phase I Trial of Flavopiridol In Relapsed Myeloma: Brief Response In t(4;14) with Significant Neutropenia. <i>Blood</i> , 2010, 116, 1933-1933.	1.4	1
208	Tablet-Based Assessment of Fatigue, Depression, and Pain In Myeloma Patients: Cohort Study of Inflammatory Cytokines and QOL Measures In the Newly Diagnosed, Patients on Lenalidomide, and Survivors.. <i>Blood</i> , 2010, 116, 3807-3807.	1.4	0
209	Allogeneic Stem Cell Transplantation for Patients with Relapsed Chemorefractory Aggressive Non-Hodgkin Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 547-553.	2.0	39
210	Improved Nonrelapse Mortality and Infection Rate with Lower Dose of Antithymocyte Globulin in Patients Undergoing Reduced-Intensity Conditioning Allogeneic Transplantation for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1422-1430.	2.0	89
211	Phase I Adjuvant Radiation With Docetaxel in High-Risk Head and Neck Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2009, 32, 396-400.	1.3	4
212	Lenalidomide, Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Newly Diagnosed Multiple Myeloma: Updated Results of Phase I/II MMRC Trial.. <i>Blood</i> , 2009, 114, 132-132.	1.4	7
213	Phase III Intergroup Study of Lenalidomide (CC-5013) Versus Placebo Maintenance Therapy Following Single Autologous Stem Cell Transplant for Multiple Myeloma (CALGB 100104): Initial Report of Patient Accrual and Adverse Events.. <i>Blood</i> , 2009, 114, 3416-3416.	1.4	8
214	IPH2101, a Novel Anti-Inhibitory KIR Monoclonal Antibody, and Lenalidomide Combine to Enhance the Natural Killer (NK) Cell Versus Multiple Myeloma (MM) Effect.. <i>Blood</i> , 2009, 114, 3870-3870.	1.4	1
215	Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM).. <i>Blood</i> , 2009, 114, 431-431.	1.4	13
216	Induced Resistance to Bortezomib in Preclinical Model of Waldenstrom Macroglobulinemia Is Associated with Bcl-2 Upregulation.. <i>Blood</i> , 2009, 114, 4919-4919.	1.4	14

#	ARTICLE	IF	CITATIONS
217	Characterization of Early Natural Killer Cell Reconstitution Following Autologous Transplantation in Multiple Myeloma.. Blood, 2009, 114, 4641-4641.	1.4	0
218	Phase I Trial of Lenalidomide and CCI-779 in Patients with Relapsed Multiple Myeloma.. Blood, 2009, 114, 2884-2884.	1.4	7
219	p53-Inducible Micrnas 192 and 215 Regulate p53 Expression and IGF1 Axis in Multiple Myeloma.. Blood, 2009, 114, 1973-1973.	1.4	0
220	Novel Monoclonal Antibody Enhances Natural Killer (NK) Cell Cytotoxicity against Multiple Myeloma (MM): Interim Phase 1 Trial Results.. Blood, 2009, 114, 2880-2880.	1.4	1
221	Phase II clinical trial of arsenic trioxide with liposomal doxorubicin, vincristine, and dexamethasone in newly diagnosed multiple myeloma. Leukemia Research, 2008, 32, 1295-1298.	0.8	12
222	The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma. Biology of Blood and Marrow Transplantation, 2008, 14, 351-352.	2.0	8
223	Addition of Infliximab to Standard Acute Graft-versus-Host Disease Prophylaxis following Allogeneic Peripheral Blood Cell Transplantation. Biology of Blood and Marrow Transplantation, 2008, 14, 783-789.	2.0	68
224	Development and Validation of a Highly Sensitive Liquid Chromatography/Mass Spectrometry Method for Simultaneous Quantification of Lenalidomide and Flavopiridol in Human Plasma. Therapeutic Drug Monitoring, 2008, 30, 620-627.	2.0	27
225	Phase 1 Clinical Trial of NPI-0052, a Novel Proteasome Inhibitor in Patients with Multiple Myeloma. Blood, 2008, 112, 2770-2770.	1.4	19
226	Hospital Care of Pathological Vertebral Fracture (PVF) in Multiple Myeloma (MM) Patients: Burden of Illness and Patterns of Care. Blood, 2008, 112, 2409-2409.	1.4	0
227	Attainment of Minimal Residual Disease Negative State Is Crucial for Successful Outcome of Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation in Advanced Chronic Lymphocytic Leukemia (CLL).. Blood, 2008, 112, 2170-2170.	1.4	0
228	Allogeneic Stem Cell Transplantation for Patients with Chemo-Refractory or Progressive Aggressive Non-Hodgkinâ€™s Lymphomas.. Blood, 2008, 112, 3265-3265.	1.4	0
229	Clinical Utility of Autopsy after Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2007, 13, 26-30.	2.0	15
230	Ex vivo expansion of umbilical cord blood stem cells for transplantation: growing knowledge from the hematopoietic niche. Bone Marrow Transplantation, 2007, 39, 11-23.	2.4	190
231	Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epsteinâ€™Barr virus DNA PCR. Bone Marrow Transplantation, 2007, 39, 249-251.	2.4	19
232	The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Patients with Multiple Myeloma.. Blood, 2007, 110, 5129-5129.	1.4	0
233	Retrospective utility of bronchoscopy after hematopoietic stem cell transplant. Bone Marrow Transplantation, 2006, 38, 693-698.	2.4	55
234	Evaluation of pulmonary infiltrates in patients after stem cell transplantation. Hematology, 2005, 10, 469-481.	1.5	7

#	ARTICLE	IF	CITATIONS
235	Autopsies Post Hematopoietic Stem Cell Transplant: A Reassessment of Their Role in Patient Management.. Blood, 2005, 106, 1332-1332.	1.4	1
236	Mucosal protection by cytokines. Psychophysiology, 2005, 4, 446-53.	1.1	9
237	Graft-versus-host disease of the skin: life and death on the epidermal edge. Biology of Blood and Marrow Transplantation, 2004, 10, 366-372.	2.0	34
238	Title is missing!. Cardiovascular Engineering (Dordrecht, Netherlands), 2002, 2, 33-35.	1.0	0
239	Phase II evaluation of paclitaxel in combination with carboplatin in advanced head and neck carcinoma. Cancer, 2001, 92, 2334-2340.	4.1	51
240	Wavelet analysis of SAECG to identify patients with conduction defects at risk for sudden cardiac death. Biomedical Sciences Instrumentation, 1997, 33, 497-502.	0.2	2
241	Symphony: view-driven software architecture reconstruction. , 0, , .		68